Cerebrospinal Fluid of ALS Patients Has Reduced Levels of Anti-Inflammatory Protein, Revealing Potential New Therapeutic Target

Cerebrospinal Fluid of ALS Patients Has Reduced Levels of Anti-Inflammatory Protein, Revealing Potential New Therapeutic Target

Researchers from the Institute of Drug Research at the The Hebrew University in Israel have revealed that patients with amyotrophic lateral sclerosis (ALS) have low levels of the anti-inflammatory protein alpha-1-antitrypsin (AAT) in their cerebrospinal fluid (CSF). The findings have been published in the Journal of Neuroinflammation in the study…

EMA Recommends Filing for Masitinib Conditional Marketing Authorization to Treat ALS

Rapporteurs appointed by the European Medicines Agency (EMA) have recommended that AB Science SA’s combined treatment ‘masitinib with riluzole’ in the treatment of adults with amyotrophic lateral sclerosis (ALS) should be filed for conditional marketing authorization. AB Science specializes in developing and marketing protein kinase inhibitors (PKIs), a class of targeted proteins…

Progranulin Levels in Blood Cannot Serve as a Biomarker for ALS, Study Reports

Blood serum levels of progranulin, a key protein to both neuronal survival and neurodegenerative diseases, are not adequate measures of progranulin levels in the brain. As such, they cannot serve as a biomarker for diseases ranging from Alzheimer’s to amyotrophic lateral sclerosis (ALS), researchers report in a study titled “Serum Levels of Progranulin…

Stem Cell Therapy: Alternative Treatment for ALS

Amyotrophic lateral sclerosis is a progressive neurodegenerative disease that causes the muscles to slowly shut down. Swiss Medica shared this video where a patient from the UK talks about how an alternative treatment with stem cell therapy has helped and improved her life with ALS.

Lymphoma Drug, AMD3100, Shows Promise in a Mouse Model of ALS

A recent study in mice could provide the first step toward a new way of treating amylotrophic lateral sclerosis (ALS). The research report, “Chronic administration of AMD3100 increases survival and alleviates pathology in SOD1G93A mice model of ALS,“ was published on May 26 in the Journal of Neuroinflammation. In…